Head-to-head evidence
VG-3927 vs VHB937
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: TREM2 · full Alzheimer's Disease pipeline
VG-3927
Developed by Sanofi
NCT06343636 · Phase 1 · completed
The healthy-volunteer part of this trial randomly assigned participants to VG-3927 or a matching placebo under double-blind conditions, which is a real controlled design, but the Alzheimer's disease group received a single open-label dose with no comparator. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
VHB937
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2028 · NCT07094516 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: VG-3927's landscape · VHB937's landscape